US Broker Ratings

Tyra Biosciences, Inc. (TYRA) Stock Analysis: A Promising 37.54% Potential Upside with Strong Buy Ratings

Tyra Biosciences, Inc. (NASDAQ: TYRA) has emerged as a compelling player in the biotechnology sector, captivating investor interest with its innovative approach to precision medicine. With a current market capitalization..

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Exploring a Potential 185% Upside in the Medical Devices Sector

Treace Medical Concepts, Inc. (NASDAQ: TMCI) is a name that has been capturing attention within the healthcare sector, specifically in the medical devices industry. With a market capitalization of $87.2..

Autolus Therapeutics plc (AUTL) Stock Analysis: Exploring the 515% Potential Upside

For investors with an appetite for high-risk, high-reward opportunities in the biotechnology sector, Autolus Therapeutics plc (NASDAQ: AUTL) offers a compelling narrative. Headquartered in London, this clinical-stage biopharmaceutical company focuses..

Definitive Healthcare Corp. (DH) Stock Analysis: An Insight into Its 145% Potential Upside

Definitive Healthcare Corp. (NASDAQ: DH) is garnering attention from investors with its intriguing financial metrics and substantial potential upside. Despite some challenges, the healthcare information service provider continues to present..

Orthofix Medical Inc. (OFIX) Stock Analysis: Unlocking a 43% Potential Upside

Orthofix Medical Inc. (NASDAQ: OFIX), a prominent player in the healthcare sector, particularly within the medical devices industry, is capturing investor attention with its promising growth potential. Headquartered in Lewisville,..

Arbutus Biopharma (ABUS) Stock Analysis: Exploring a 32% Potential Upside in the Biotech Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS) stands as a noteworthy player in the healthcare sector, specifically within the biotechnology industry in the United States. With a market capitalization of approximately $830.84..

Replimune Group, Inc. (REPL) Stock Analysis: Why Investors Should Consider a 69.62% Potential Upside

Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company at the forefront of developing oncolytic immunotherapies for cancer treatment, presents a compelling opportunity for investors, particularly given its significant potential upside..

Xencor, Inc. (XNCR) Stock Analysis: Exploring a Potential 148.35% Upside in Biotechnology

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company, has recently captured the attention of investors with its compelling growth potential in the biotechnology sector. Despite current challenges, including a downturn..

PureTech Health plc (PRTC) Stock Analysis: Unprecedented Revenue Growth Sparks Investor Interest

PureTech Health plc (PRTC), a pioneering biotechnology firm based in Boston, Massachusetts, is catching the eye of investors with a remarkable revenue growth rate of 542.70%. As a company focused..

Semler Scientific, Inc. (SMLR) Stock Analysis: Unpacking a 258% Upside Potential

Investors seeking opportunities in the healthcare sector should take a closer look at Semler Scientific, Inc. (NASDAQ: SMLR), a Santa Clara-based medical device company that is currently generating significant buzz...

Iovance Biotherapeutics (IOVA) Stock Analysis: Exploring a 121% Upside Potential in the Biotech Sector

Investors looking for growth opportunities in the biotech sector should turn their attention to Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). This commercial-stage biopharmaceutical company, headquartered in San Carlos, California, focuses on..

EyePoint, Inc. (EYPT) Stock Analysis: A Biotech with 166% Upside Potential

Investors focused on high-growth opportunities in the biotechnology sector might find EyePoint, Inc. (NASDAQ: EYPT) an intriguing option. The company, with a market capitalization of $1.17 billion, is actively developing..

MBX Biosciences, Inc. (MBX) Stock Analysis: Potential 118.96% Upside Amidst Robust Pipeline in Biotechnology

MBX Biosciences, Inc. (MBX) stands at the forefront of innovation in the biotechnology sector, developing precision peptide therapies aimed at addressing critical endocrine and metabolic disorders. With a market capitalization..

Precigen, Inc. (PGEN) Stock Analysis: Exploring a 159% Upside in the Biotech Sector

Precigen, Inc. (NASDAQ: PGEN) is capturing the spotlight in the healthcare sector with a remarkable potential upside of 159.15%, according to analyst ratings. As a pioneering entity in the biotechnology..

Personalis, Inc. (PSNL) Investor Outlook: Navigating a 73% Potential Upside in the Diagnostics Sector

Personalis, Inc. (PSNL) is making waves in the healthcare sector, particularly within the diagnostics and research industry. Headquartered in Fremont, California, Personalis specializes in advanced cancer genomic tests, catering to..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Navigating Challenges with a 65.76% Potential Upside

Fulgent Genetics, Inc. (NASDAQ: FLGT) stands at an intriguing junction, presenting both challenges and opportunities for investors. With a market capitalization of $458.47 million, this healthcare company, specializing in diagnostics..

Zenas BioPharma, Inc. (ZBIO) Stock Analysis: Potential 66% Upside with Strong Analyst Support

Zenas BioPharma, Inc. (ZBIO), a clinical-stage biopharmaceutical innovator, stands out in the biotechnology sector with its impressive potential upside of 66.33%, as noted by analysts. With a market capitalization of..

Prothena Corporation plc (PRTA): Unveiling a 120% Potential Upside Amidst Clinical Innovations

For investors eyeing opportunities in the biotechnology sector, Prothena Corporation plc (NASDAQ: PRTA) presents an intriguing case. With a market capitalization of $501.19 million, this Ireland-based biotech firm is making..

AtaiBeckley Inc. (ATAI) Stock Analysis: Biotech Innovator with 252% Potential Upside

AtaiBeckley Inc. (ATAI), a burgeoning player in the biotechnology sector, is capturing investor attention with its innovative approach to mental health treatments. Despite recent price volatility, the company’s stock offers..

Oculis Holding AG (OCS) Stock Analysis: A 74.98% Potential Upside in the Biotech Sector

Investors with an eye on the biotechnology sector may find Oculis Holding AG (NASDAQ: OCS) an intriguing prospect, given its compelling growth potential and strategic focus on ophthalmic and neuro-ophthalmic..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds